Eric Lefkofsky, founder of Tempus, a leader in Artificial Intelligence and precision medicine, released its new short term, on demand, cloud based data and analytics platform, LENS. LENS, along with Tempus, gives researchers access to numerous molecular and clinical data sets plus the latest artificial intelligence analytical tools. According to Eric Lefkosfky, LENS will lead to faster development and discovery of new drugs and treatments. Also, since access to LENS is short term and only when necessary for researchers, it can reduce costs for the health care system.
The ability to have this important data at researchers’, physicians’, scientists’ and analysts’ fingertips will revolutionize research and development. With access to one of the world’s largest libraries of clinical and molecular data including Tempus’ data for tumor and normal genetic markers both researchers and physicians can have new ideas about their subject in almost real time. With the help of the CEO, Eric Lefkofsky, Tempus has collected up to $ 200 million.
Also, it has been reported that the founder contributed an undisclosed amount of money for the same project. LENS and Tempus will offer the ability to gather insights that will not be available anywhere else. It is a revolutionary tool in the biotech industry. Eric Lefkofsky has pointed out that LENS provides users the tools and the means to rapidly find answers to important questions. Whether it be to assess patients for research and publication, or to find potential candidates for a new treatment or to understand certain trends among potential populations, LENS and Tempus are blazing new trails in research and development.
Forbes reviews on Eric Lefkosky and Tempus Pharmaceutical Firm https://www.forbes.com.br/negocios/2020/12/com-o-bilionario-eric-lefkofsky-no-comando-a-empresa-de-medicina-tempus-levanta-us-200-milhoes-em-investimentos/